ESTRO 2022 - Abstract Book

S103

Abstract book

ESTRO 2022

Work was performed in RayStation Research version 9B in collaboration with RaySearch Laboratories AB (Stockholm, Sweden).

Results The STRIDeR pathway was successfully used in all 21 cases, with clinically acceptable plans created in 20/21 (optimal clinical goals achieved in 12, relaxation of optimal clinical goals or incorporation of recovery required in 7 and reduced prescription dose required in 1; Fig 2). Compared to plans produced using the more laborious manual method, less clinical goal relaxation was required or a higher reRT dose could be prescribed in 3/21 cases.

Conclusion The STRIDeR pathway uses background dose for scientifically meaningful reRT treatment planning in a commercial TPS. This provides a standardised approach that offers more informed reRT, improved cumulative OAR dose evaluation, and the potential for enhanced understanding of OAR reRT tolerance.